[Study on the pharmacokinetics of Imipenem cilastatin in burn patients during the acute phase].
OBJECTIVE
To investigate the pharmacokinetic characteristics of Imipenem/cilastatin in burn patients during the acute phase.


METHODS
Imipenem concentrations in the plasma, blister and, interstitial fluids and urine of 6 burn patients (P group) were determined during the acute phase by high performance liquid chromatography after the first initial dose. Pharmacokinetic parameters were thus produced and statistically analyzed by program package STAT 5. Ten healthy volunteers served as control group (C group).


RESULTS
Compared to those in control group, pharmacokinetic parameters of Imipenem exhibited evident difference, such as prolonged half-life [(1.56 plus minus 0.55) h vs (1.06 plus minus 0.24) h] and enlarged distributing volume (16.16 plus minus 4.26) vs (13.96 plus minus 7.10). Imipenem could be detected in the blister and interstitial fluids of burn patients 1 hr after the initial dose. Renal clearance of Imipenem was positively correlated to creatinine clearance (r = 0.5834).


CONCLUSIONS
The intervals between doses should better be prolonged when loaded-dosage of Imipenem was administered in burn patients during the acute phase. Imipenem could penetrate II and III degree burn wound when given in the acute phase. Attention should be paid to renal function when Imipenem was given.
Wang
H
H
Chengdu, General Hospital of Military Command Chengdu, Sichuan 610083, P. R. China.
Peng
Y
Y
Xiao
G
G
D000328:Adult; D002056:Burns / Q000378:metabolism*; D015377:Cilastatin / Q000493:pharmacokinetics*; D000077728:Cilastatin, Imipenem Drug Combination; D004338:Drug Combinations; D005260:Female; D006801:Humans; D015378:Imipenem / Q000493:pharmacokinetics*; D007668:Kidney / Q000378:metabolism; D008297:Male; D008657:Metabolic Clearance Rate
D004338:Drug Combinations; D015377:Cilastatin; D015378:Imipenem; D000077728:Cilastatin, Imipenem Drug Combination